Skip to main content
. 2020 Apr 20;40(4):453–458. doi: 10.12122/j.issn.1673-4254.2020.04.01

2.

2

Relapse-free survival of the patients with different baseline neutrophil-lymphocyte ratios (NLR) during infliximab therapy.